nodes	percent_of_prediction	percent_of_DWPC	metapath
Nelarabine—Speech disorder—Methotrexate—psoriatic arthritis	0.00394	0.00411	CcSEcCtD
Nelarabine—Neuropathy—Prednisone—psoriatic arthritis	0.00381	0.00398	CcSEcCtD
Nelarabine—Hyperbilirubinaemia—Methotrexate—psoriatic arthritis	0.00373	0.00389	CcSEcCtD
Nelarabine—Osteoarthritis—Triamcinolone—psoriatic arthritis	0.00373	0.00389	CcSEcCtD
Nelarabine—Osteoarthritis—Methylprednisolone—psoriatic arthritis	0.00372	0.00388	CcSEcCtD
Nelarabine—Nausea—Auranofin—psoriatic arthritis	0.00371	0.00387	CcSEcCtD
Nelarabine—DCK—Desoximetasone—Methylprednisolone—psoriatic arthritis	0.00367	0.0885	CbGdCrCtD
Nelarabine—Hyperuricaemia—Methotrexate—psoriatic arthritis	0.00366	0.00381	CcSEcCtD
Nelarabine—DCK—Desoximetasone—Betamethasone—psoriatic arthritis	0.00361	0.0871	CbGdCrCtD
Nelarabine—DCK—Desoximetasone—Dexamethasone—psoriatic arthritis	0.00361	0.0871	CbGdCrCtD
Nelarabine—Dysarthria—Methotrexate—psoriatic arthritis	0.00359	0.00374	CcSEcCtD
Nelarabine—Muscular weakness—Prednisolone—psoriatic arthritis	0.00358	0.00373	CcSEcCtD
Nelarabine—DCK—Diflorasone—Methylprednisolone—psoriatic arthritis	0.00356	0.0859	CbGdCrCtD
Nelarabine—Abdominal distension—Prednisolone—psoriatic arthritis	0.00353	0.00368	CcSEcCtD
Nelarabine—DCK—Desoximetasone—Triamcinolone—psoriatic arthritis	0.00353	0.0851	CbGdCrCtD
Nelarabine—Sepsis—Prednisone—psoriatic arthritis	0.00352	0.00367	CcSEcCtD
Nelarabine—DCK—Diflorasone—Betamethasone—psoriatic arthritis	0.0035	0.0846	CbGdCrCtD
Nelarabine—DCK—Diflorasone—Dexamethasone—psoriatic arthritis	0.0035	0.0846	CbGdCrCtD
Nelarabine—Blood uric acid increased—Methotrexate—psoriatic arthritis	0.00345	0.0036	CcSEcCtD
Nelarabine—Lethargy—Dexamethasone—psoriatic arthritis	0.00345	0.0036	CcSEcCtD
Nelarabine—Lethargy—Betamethasone—psoriatic arthritis	0.00345	0.0036	CcSEcCtD
Nelarabine—DCK—Diflorasone—Triamcinolone—psoriatic arthritis	0.00342	0.0826	CbGdCrCtD
Nelarabine—Osteoarthritis—Dexamethasone—psoriatic arthritis	0.00338	0.00353	CcSEcCtD
Nelarabine—Osteoarthritis—Betamethasone—psoriatic arthritis	0.00338	0.00353	CcSEcCtD
Nelarabine—DCK—Desoximetasone—Prednisone—psoriatic arthritis	0.00335	0.0808	CbGdCrCtD
Nelarabine—Muscular weakness—Triamcinolone—psoriatic arthritis	0.00329	0.00343	CcSEcCtD
Nelarabine—Muscular weakness—Methylprednisolone—psoriatic arthritis	0.00328	0.00342	CcSEcCtD
Nelarabine—Depressed level of consciousness—Methotrexate—psoriatic arthritis	0.00328	0.00342	CcSEcCtD
Nelarabine—DCK—Desoximetasone—Prednisolone—psoriatic arthritis	0.00327	0.0789	CbGdCrCtD
Nelarabine—DCK—Diflorasone—Prednisone—psoriatic arthritis	0.00325	0.0784	CbGdCrCtD
Nelarabine—Abdominal distension—Triamcinolone—psoriatic arthritis	0.00324	0.00338	CcSEcCtD
Nelarabine—Abdominal distension—Methylprednisolone—psoriatic arthritis	0.00324	0.00338	CcSEcCtD
Nelarabine—DCK—Diflorasone—Prednisolone—psoriatic arthritis	0.00317	0.0765	CbGdCrCtD
Nelarabine—Amnesia—Prednisone—psoriatic arthritis	0.00314	0.00327	CcSEcCtD
Nelarabine—Coma—Methotrexate—psoriatic arthritis	0.0031	0.00323	CcSEcCtD
Nelarabine—Hypokalaemia—Betamethasone—psoriatic arthritis	0.00308	0.00321	CcSEcCtD
Nelarabine—Hypokalaemia—Dexamethasone—psoriatic arthritis	0.00308	0.00321	CcSEcCtD
Nelarabine—Neoplasm—Methotrexate—psoriatic arthritis	0.00307	0.0032	CcSEcCtD
Nelarabine—Neuropathy peripheral—Prednisolone—psoriatic arthritis	0.00306	0.0032	CcSEcCtD
Nelarabine—Lethargy—Prednisone—psoriatic arthritis	0.00301	0.00314	CcSEcCtD
Nelarabine—Muscular weakness—Betamethasone—psoriatic arthritis	0.00298	0.00311	CcSEcCtD
Nelarabine—Muscular weakness—Dexamethasone—psoriatic arthritis	0.00298	0.00311	CcSEcCtD
Nelarabine—Osteoarthritis—Prednisone—psoriatic arthritis	0.00295	0.00307	CcSEcCtD
Nelarabine—Sepsis—Methotrexate—psoriatic arthritis	0.00294	0.00307	CcSEcCtD
Nelarabine—Infestation NOS—Methylprednisolone—psoriatic arthritis	0.00287	0.00299	CcSEcCtD
Nelarabine—Infestation—Methylprednisolone—psoriatic arthritis	0.00287	0.00299	CcSEcCtD
Nelarabine—Neuropathy peripheral—Triamcinolone—psoriatic arthritis	0.00282	0.00294	CcSEcCtD
Nelarabine—Neuropathy peripheral—Methylprednisolone—psoriatic arthritis	0.00281	0.00293	CcSEcCtD
Nelarabine—Epistaxis—Triamcinolone—psoriatic arthritis	0.00271	0.00283	CcSEcCtD
Nelarabine—Hypokalaemia—Prednisone—psoriatic arthritis	0.00268	0.0028	CcSEcCtD
Nelarabine—Hyperglycaemia—Betamethasone—psoriatic arthritis	0.00264	0.00275	CcSEcCtD
Nelarabine—Hyperglycaemia—Dexamethasone—psoriatic arthritis	0.00264	0.00275	CcSEcCtD
Nelarabine—Muscular weakness—Prednisone—psoriatic arthritis	0.0026	0.00271	CcSEcCtD
Nelarabine—Abdominal distension—Prednisone—psoriatic arthritis	0.00256	0.00267	CcSEcCtD
Nelarabine—Neuropathy peripheral—Dexamethasone—psoriatic arthritis	0.00256	0.00267	CcSEcCtD
Nelarabine—Neuropathy peripheral—Betamethasone—psoriatic arthritis	0.00256	0.00267	CcSEcCtD
Nelarabine—Connective tissue disorder—Methylprednisolone—psoriatic arthritis	0.00253	0.00264	CcSEcCtD
Nelarabine—Lethargy—Methotrexate—psoriatic arthritis	0.00251	0.00262	CcSEcCtD
Nelarabine—Osteoarthritis—Methotrexate—psoriatic arthritis	0.00246	0.00257	CcSEcCtD
Nelarabine—Eye disorder—Methylprednisolone—psoriatic arthritis	0.00241	0.00251	CcSEcCtD
Nelarabine—Cardiac disorder—Methylprednisolone—psoriatic arthritis	0.00239	0.00249	CcSEcCtD
Nelarabine—Neutropenia—Prednisone—psoriatic arthritis	0.00238	0.00248	CcSEcCtD
Nelarabine—Angiopathy—Methylprednisolone—psoriatic arthritis	0.00234	0.00244	CcSEcCtD
Nelarabine—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.00232	0.00242	CcSEcCtD
Nelarabine—Ataxia—Methotrexate—psoriatic arthritis	0.00232	0.00242	CcSEcCtD
Nelarabine—Vision blurred—Prednisolone—psoriatic arthritis	0.0023	0.0024	CcSEcCtD
Nelarabine—Hyperglycaemia—Prednisone—psoriatic arthritis	0.0023	0.0024	CcSEcCtD
Nelarabine—Depression—Prednisone—psoriatic arthritis	0.00226	0.00236	CcSEcCtD
Nelarabine—Mental disorder—Methylprednisolone—psoriatic arthritis	0.00225	0.00235	CcSEcCtD
Nelarabine—Malnutrition—Methylprednisolone—psoriatic arthritis	0.00224	0.00234	CcSEcCtD
Nelarabine—Neuropathy peripheral—Prednisone—psoriatic arthritis	0.00223	0.00232	CcSEcCtD
Nelarabine—Dysgeusia—Triamcinolone—psoriatic arthritis	0.0022	0.00229	CcSEcCtD
Nelarabine—Eye disorder—Betamethasone—psoriatic arthritis	0.00219	0.00228	CcSEcCtD
Nelarabine—Eye disorder—Dexamethasone—psoriatic arthritis	0.00219	0.00228	CcSEcCtD
Nelarabine—Back pain—Triamcinolone—psoriatic arthritis	0.00217	0.00227	CcSEcCtD
Nelarabine—Loss of consciousness—Prednisolone—psoriatic arthritis	0.00215	0.00224	CcSEcCtD
Nelarabine—Angiopathy—Betamethasone—psoriatic arthritis	0.00212	0.00222	CcSEcCtD
Nelarabine—Angiopathy—Dexamethasone—psoriatic arthritis	0.00212	0.00222	CcSEcCtD
Nelarabine—Convulsion—Prednisolone—psoriatic arthritis	0.00212	0.00221	CcSEcCtD
Nelarabine—Connective tissue disorder—Prednisone—psoriatic arthritis	0.002	0.00209	CcSEcCtD
Nelarabine—Oedema—Prednisolone—psoriatic arthritis	0.00199	0.00208	CcSEcCtD
Nelarabine—Neutropenia—Methotrexate—psoriatic arthritis	0.00199	0.00208	CcSEcCtD
Nelarabine—Loss of consciousness—Triamcinolone—psoriatic arthritis	0.00197	0.00206	CcSEcCtD
Nelarabine—Loss of consciousness—Methylprednisolone—psoriatic arthritis	0.00197	0.00205	CcSEcCtD
Nelarabine—Cough—Triamcinolone—psoriatic arthritis	0.00196	0.00204	CcSEcCtD
Nelarabine—Convulsion—Triamcinolone—psoriatic arthritis	0.00195	0.00203	CcSEcCtD
Nelarabine—Convulsion—Methylprednisolone—psoriatic arthritis	0.00194	0.00203	CcSEcCtD
Nelarabine—Myalgia—Triamcinolone—psoriatic arthritis	0.00191	0.00199	CcSEcCtD
Nelarabine—Pneumonia—Methotrexate—psoriatic arthritis	0.00191	0.00199	CcSEcCtD
Nelarabine—Myalgia—Methylprednisolone—psoriatic arthritis	0.00191	0.00199	CcSEcCtD
Nelarabine—Arthralgia—Methylprednisolone—psoriatic arthritis	0.00191	0.00199	CcSEcCtD
Nelarabine—Eye disorder—Prednisone—psoriatic arthritis	0.0019	0.00199	CcSEcCtD
Nelarabine—Infestation—Methotrexate—psoriatic arthritis	0.0019	0.00198	CcSEcCtD
Nelarabine—Infestation NOS—Methotrexate—psoriatic arthritis	0.0019	0.00198	CcSEcCtD
Nelarabine—Depression—Methotrexate—psoriatic arthritis	0.00189	0.00197	CcSEcCtD
Nelarabine—Stomatitis—Methotrexate—psoriatic arthritis	0.00185	0.00193	CcSEcCtD
Nelarabine—Angiopathy—Prednisone—psoriatic arthritis	0.00185	0.00193	CcSEcCtD
Nelarabine—Confusional state—Methylprednisolone—psoriatic arthritis	0.00184	0.00192	CcSEcCtD
Nelarabine—Oedema—Triamcinolone—psoriatic arthritis	0.00183	0.00191	CcSEcCtD
Nelarabine—Infection—Triamcinolone—psoriatic arthritis	0.00182	0.0019	CcSEcCtD
Nelarabine—Infection—Methylprednisolone—psoriatic arthritis	0.00182	0.0019	CcSEcCtD
Nelarabine—Insomnia—Prednisolone—psoriatic arthritis	0.0018	0.00188	CcSEcCtD
Nelarabine—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.00179	0.00187	CcSEcCtD
Nelarabine—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.00179	0.00187	CcSEcCtD
Nelarabine—Loss of consciousness—Betamethasone—psoriatic arthritis	0.00179	0.00187	CcSEcCtD
Nelarabine—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.00179	0.00187	CcSEcCtD
Nelarabine—Epistaxis—Methotrexate—psoriatic arthritis	0.00179	0.00187	CcSEcCtD
Nelarabine—Paraesthesia—Prednisolone—psoriatic arthritis	0.00179	0.00187	CcSEcCtD
Nelarabine—Mental disorder—Prednisone—psoriatic arthritis	0.00179	0.00186	CcSEcCtD
Nelarabine—Malnutrition—Prednisone—psoriatic arthritis	0.00177	0.00185	CcSEcCtD
Nelarabine—Convulsion—Dexamethasone—psoriatic arthritis	0.00177	0.00184	CcSEcCtD
Nelarabine—Convulsion—Betamethasone—psoriatic arthritis	0.00177	0.00184	CcSEcCtD
Nelarabine—Myalgia—Dexamethasone—psoriatic arthritis	0.00173	0.00181	CcSEcCtD
Nelarabine—Myalgia—Betamethasone—psoriatic arthritis	0.00173	0.00181	CcSEcCtD
Nelarabine—Hypotension—Methylprednisolone—psoriatic arthritis	0.00171	0.00178	CcSEcCtD
Nelarabine—Pain—Prednisolone—psoriatic arthritis	0.0017	0.00178	CcSEcCtD
Nelarabine—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.00168	0.00175	CcSEcCtD
Nelarabine—Vision blurred—Prednisone—psoriatic arthritis	0.00167	0.00174	CcSEcCtD
Nelarabine—Urethral disorder—Methotrexate—psoriatic arthritis	0.00167	0.00174	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.00167	0.00174	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.00167	0.00174	CcSEcCtD
Nelarabine—Oedema—Dexamethasone—psoriatic arthritis	0.00166	0.00173	CcSEcCtD
Nelarabine—Oedema—Betamethasone—psoriatic arthritis	0.00166	0.00173	CcSEcCtD
Nelarabine—Insomnia—Triamcinolone—psoriatic arthritis	0.00166	0.00173	CcSEcCtD
Nelarabine—Insomnia—Methylprednisolone—psoriatic arthritis	0.00165	0.00173	CcSEcCtD
Nelarabine—Infection—Dexamethasone—psoriatic arthritis	0.00165	0.00172	CcSEcCtD
Nelarabine—Infection—Betamethasone—psoriatic arthritis	0.00165	0.00172	CcSEcCtD
Nelarabine—Paraesthesia—Triamcinolone—psoriatic arthritis	0.00165	0.00172	CcSEcCtD
Nelarabine—Feeling abnormal—Prednisolone—psoriatic arthritis	0.00164	0.00171	CcSEcCtD
Nelarabine—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.00164	0.00171	CcSEcCtD
Nelarabine—Anaemia—Prednisone—psoriatic arthritis	0.00164	0.00171	CcSEcCtD
Nelarabine—Dyspnoea—Triamcinolone—psoriatic arthritis	0.00163	0.0017	CcSEcCtD
Nelarabine—Nervous system disorder—Betamethasone—psoriatic arthritis	0.00163	0.0017	CcSEcCtD
Nelarabine—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.00163	0.0017	CcSEcCtD
Nelarabine—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.00163	0.0017	CcSEcCtD
Nelarabine—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.00163	0.0017	CcSEcCtD
Nelarabine—Eye disorder—Methotrexate—psoriatic arthritis	0.00159	0.00166	CcSEcCtD
Nelarabine—Anorexia—Dexamethasone—psoriatic arthritis	0.00159	0.00165	CcSEcCtD
Nelarabine—Anorexia—Betamethasone—psoriatic arthritis	0.00159	0.00165	CcSEcCtD
Nelarabine—Cardiac disorder—Methotrexate—psoriatic arthritis	0.00158	0.00165	CcSEcCtD
Nelarabine—Fatigue—Triamcinolone—psoriatic arthritis	0.00158	0.00165	CcSEcCtD
Nelarabine—Fatigue—Methylprednisolone—psoriatic arthritis	0.00158	0.00164	CcSEcCtD
Nelarabine—Pain—Triamcinolone—psoriatic arthritis	0.00157	0.00163	CcSEcCtD
Nelarabine—Loss of consciousness—Prednisone—psoriatic arthritis	0.00156	0.00163	CcSEcCtD
Nelarabine—Hypotension—Dexamethasone—psoriatic arthritis	0.00155	0.00162	CcSEcCtD
Nelarabine—Hypotension—Betamethasone—psoriatic arthritis	0.00155	0.00162	CcSEcCtD
Nelarabine—Angiopathy—Methotrexate—psoriatic arthritis	0.00155	0.00161	CcSEcCtD
Nelarabine—Convulsion—Prednisone—psoriatic arthritis	0.00154	0.0016	CcSEcCtD
Nelarabine—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.00154	0.0016	CcSEcCtD
Nelarabine—Chills—Methotrexate—psoriatic arthritis	0.00153	0.00159	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.00152	0.00158	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.00152	0.00158	CcSEcCtD
Nelarabine—Arthralgia—Prednisone—psoriatic arthritis	0.00151	0.00158	CcSEcCtD
Nelarabine—Myalgia—Prednisone—psoriatic arthritis	0.00151	0.00158	CcSEcCtD
Nelarabine—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.00151	0.00158	CcSEcCtD
Nelarabine—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.00151	0.00157	CcSEcCtD
Nelarabine—Insomnia—Dexamethasone—psoriatic arthritis	0.0015	0.00157	CcSEcCtD
Nelarabine—Insomnia—Betamethasone—psoriatic arthritis	0.0015	0.00157	CcSEcCtD
Nelarabine—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.0015	0.00156	CcSEcCtD
Nelarabine—Paraesthesia—Dexamethasone—psoriatic arthritis	0.00149	0.00156	CcSEcCtD
Nelarabine—Paraesthesia—Betamethasone—psoriatic arthritis	0.00149	0.00156	CcSEcCtD
Nelarabine—Mental disorder—Methotrexate—psoriatic arthritis	0.00149	0.00156	CcSEcCtD
Nelarabine—Malnutrition—Methotrexate—psoriatic arthritis	0.00148	0.00155	CcSEcCtD
Nelarabine—Dysgeusia—Methotrexate—psoriatic arthritis	0.00145	0.00151	CcSEcCtD
Nelarabine—Body temperature increased—Triamcinolone—psoriatic arthritis	0.00145	0.00151	CcSEcCtD
Nelarabine—Oedema—Prednisone—psoriatic arthritis	0.00145	0.00151	CcSEcCtD
Nelarabine—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.00145	0.00151	CcSEcCtD
Nelarabine—Decreased appetite—Betamethasone—psoriatic arthritis	0.00145	0.00151	CcSEcCtD
Nelarabine—Decreased appetite—Dexamethasone—psoriatic arthritis	0.00145	0.00151	CcSEcCtD
Nelarabine—Infection—Prednisone—psoriatic arthritis	0.00144	0.0015	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00144	0.0015	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00144	0.0015	CcSEcCtD
Nelarabine—Back pain—Methotrexate—psoriatic arthritis	0.00143	0.0015	CcSEcCtD
Nelarabine—Fatigue—Dexamethasone—psoriatic arthritis	0.00143	0.0015	CcSEcCtD
Nelarabine—Fatigue—Betamethasone—psoriatic arthritis	0.00143	0.0015	CcSEcCtD
Nelarabine—Pain—Dexamethasone—psoriatic arthritis	0.00142	0.00148	CcSEcCtD
Nelarabine—Pain—Betamethasone—psoriatic arthritis	0.00142	0.00148	CcSEcCtD
Nelarabine—Nervous system disorder—Prednisone—psoriatic arthritis	0.00142	0.00148	CcSEcCtD
Nelarabine—Vision blurred—Methotrexate—psoriatic arthritis	0.0014	0.00146	CcSEcCtD
Nelarabine—Anorexia—Prednisone—psoriatic arthritis	0.00138	0.00144	CcSEcCtD
Nelarabine—Anaemia—Methotrexate—psoriatic arthritis	0.00137	0.00143	CcSEcCtD
Nelarabine—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.00137	0.00143	CcSEcCtD
Nelarabine—Feeling abnormal—Betamethasone—psoriatic arthritis	0.00137	0.00143	CcSEcCtD
Nelarabine—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.00136	0.00142	CcSEcCtD
Nelarabine—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.00136	0.00142	CcSEcCtD
Nelarabine—Leukopenia—Methotrexate—psoriatic arthritis	0.00133	0.00138	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.00132	0.00138	CcSEcCtD
Nelarabine—Dizziness—Prednisolone—psoriatic arthritis	0.00132	0.00137	CcSEcCtD
Nelarabine—Asthenia—Triamcinolone—psoriatic arthritis	0.00131	0.00137	CcSEcCtD
Nelarabine—Abdominal pain—Dexamethasone—psoriatic arthritis	0.00131	0.00137	CcSEcCtD
Nelarabine—Body temperature increased—Betamethasone—psoriatic arthritis	0.00131	0.00137	CcSEcCtD
Nelarabine—Abdominal pain—Betamethasone—psoriatic arthritis	0.00131	0.00137	CcSEcCtD
Nelarabine—Body temperature increased—Dexamethasone—psoriatic arthritis	0.00131	0.00137	CcSEcCtD
Nelarabine—Asthenia—Methylprednisolone—psoriatic arthritis	0.00131	0.00137	CcSEcCtD
Nelarabine—Insomnia—Prednisone—psoriatic arthritis	0.00131	0.00137	CcSEcCtD
Nelarabine—Paraesthesia—Prednisone—psoriatic arthritis	0.0013	0.00136	CcSEcCtD
Nelarabine—Cough—Methotrexate—psoriatic arthritis	0.00129	0.00135	CcSEcCtD
Nelarabine—Convulsion—Methotrexate—psoriatic arthritis	0.00128	0.00134	CcSEcCtD
Nelarabine—Arthralgia—Methotrexate—psoriatic arthritis	0.00126	0.00132	CcSEcCtD
Nelarabine—Chest pain—Methotrexate—psoriatic arthritis	0.00126	0.00132	CcSEcCtD
Nelarabine—Myalgia—Methotrexate—psoriatic arthritis	0.00126	0.00132	CcSEcCtD
Nelarabine—Decreased appetite—Prednisone—psoriatic arthritis	0.00126	0.00131	CcSEcCtD
Nelarabine—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.00125	0.00131	CcSEcCtD
Nelarabine—Fatigue—Prednisone—psoriatic arthritis	0.00125	0.0013	CcSEcCtD
Nelarabine—Headache—Prednisolone—psoriatic arthritis	0.00125	0.0013	CcSEcCtD
Nelarabine—Constipation—Prednisone—psoriatic arthritis	0.00124	0.00129	CcSEcCtD
Nelarabine—Confusional state—Methotrexate—psoriatic arthritis	0.00122	0.00127	CcSEcCtD
Nelarabine—Dizziness—Triamcinolone—psoriatic arthritis	0.00121	0.00126	CcSEcCtD
Nelarabine—Dizziness—Methylprednisolone—psoriatic arthritis	0.00121	0.00126	CcSEcCtD
Nelarabine—Infection—Methotrexate—psoriatic arthritis	0.0012	0.00125	CcSEcCtD
Nelarabine—Feeling abnormal—Prednisone—psoriatic arthritis	0.00119	0.00124	CcSEcCtD
Nelarabine—Asthenia—Dexamethasone—psoriatic arthritis	0.00119	0.00124	CcSEcCtD
Nelarabine—Asthenia—Betamethasone—psoriatic arthritis	0.00119	0.00124	CcSEcCtD
Nelarabine—Nervous system disorder—Methotrexate—psoriatic arthritis	0.00119	0.00124	CcSEcCtD
Nelarabine—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.00118	0.00124	CcSEcCtD
Nelarabine—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.00118	0.00124	CcSEcCtD
Nelarabine—Nausea—Prednisolone—psoriatic arthritis	0.00118	0.00123	CcSEcCtD
Nelarabine—Vomiting—Triamcinolone—psoriatic arthritis	0.00117	0.00122	CcSEcCtD
Nelarabine—Vomiting—Methylprednisolone—psoriatic arthritis	0.00116	0.00121	CcSEcCtD
Nelarabine—Anorexia—Methotrexate—psoriatic arthritis	0.00115	0.0012	CcSEcCtD
Nelarabine—Headache—Triamcinolone—psoriatic arthritis	0.00115	0.0012	CcSEcCtD
Nelarabine—Headache—Methylprednisolone—psoriatic arthritis	0.00115	0.0012	CcSEcCtD
Nelarabine—Abdominal pain—Prednisone—psoriatic arthritis	0.00114	0.00119	CcSEcCtD
Nelarabine—Body temperature increased—Prednisone—psoriatic arthritis	0.00114	0.00119	CcSEcCtD
Nelarabine—Diarrhoea—Betamethasone—psoriatic arthritis	0.00114	0.00119	CcSEcCtD
Nelarabine—Diarrhoea—Dexamethasone—psoriatic arthritis	0.00114	0.00119	CcSEcCtD
Nelarabine—Hypotension—Methotrexate—psoriatic arthritis	0.00113	0.00118	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.0011	0.00115	CcSEcCtD
Nelarabine—Dizziness—Betamethasone—psoriatic arthritis	0.0011	0.00115	CcSEcCtD
Nelarabine—Dizziness—Dexamethasone—psoriatic arthritis	0.0011	0.00115	CcSEcCtD
Nelarabine—Insomnia—Methotrexate—psoriatic arthritis	0.00109	0.00114	CcSEcCtD
Nelarabine—Nausea—Triamcinolone—psoriatic arthritis	0.00109	0.00114	CcSEcCtD
Nelarabine—Paraesthesia—Methotrexate—psoriatic arthritis	0.00109	0.00113	CcSEcCtD
Nelarabine—Nausea—Methylprednisolone—psoriatic arthritis	0.00109	0.00113	CcSEcCtD
Nelarabine—Dyspnoea—Methotrexate—psoriatic arthritis	0.00108	0.00113	CcSEcCtD
Nelarabine—Somnolence—Methotrexate—psoriatic arthritis	0.00108	0.00112	CcSEcCtD
Nelarabine—Vomiting—Dexamethasone—psoriatic arthritis	0.00106	0.0011	CcSEcCtD
Nelarabine—Vomiting—Betamethasone—psoriatic arthritis	0.00106	0.0011	CcSEcCtD
Nelarabine—Decreased appetite—Methotrexate—psoriatic arthritis	0.00105	0.0011	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.00104	0.00109	CcSEcCtD
Nelarabine—Fatigue—Methotrexate—psoriatic arthritis	0.00104	0.00109	CcSEcCtD
Nelarabine—Headache—Betamethasone—psoriatic arthritis	0.00104	0.00109	CcSEcCtD
Nelarabine—Headache—Dexamethasone—psoriatic arthritis	0.00104	0.00109	CcSEcCtD
Nelarabine—Asthenia—Prednisone—psoriatic arthritis	0.00104	0.00108	CcSEcCtD
Nelarabine—Pain—Methotrexate—psoriatic arthritis	0.00103	0.00108	CcSEcCtD
Nelarabine—Feeling abnormal—Methotrexate—psoriatic arthritis	0.000997	0.00104	CcSEcCtD
Nelarabine—Diarrhoea—Prednisone—psoriatic arthritis	0.000991	0.00103	CcSEcCtD
Nelarabine—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.00099	0.00103	CcSEcCtD
Nelarabine—Nausea—Betamethasone—psoriatic arthritis	0.000988	0.00103	CcSEcCtD
Nelarabine—Nausea—Dexamethasone—psoriatic arthritis	0.000988	0.00103	CcSEcCtD
Nelarabine—Dizziness—Prednisone—psoriatic arthritis	0.000958	0.000999	CcSEcCtD
Nelarabine—Body temperature increased—Methotrexate—psoriatic arthritis	0.000957	0.000998	CcSEcCtD
Nelarabine—Abdominal pain—Methotrexate—psoriatic arthritis	0.000957	0.000998	CcSEcCtD
Nelarabine—Vomiting—Prednisone—psoriatic arthritis	0.000921	0.000961	CcSEcCtD
Nelarabine—Headache—Prednisone—psoriatic arthritis	0.000907	0.000946	CcSEcCtD
Nelarabine—Asthenia—Methotrexate—psoriatic arthritis	0.000868	0.000906	CcSEcCtD
Nelarabine—Nausea—Prednisone—psoriatic arthritis	0.00086	0.000897	CcSEcCtD
Nelarabine—Diarrhoea—Methotrexate—psoriatic arthritis	0.000828	0.000864	CcSEcCtD
Nelarabine—Dizziness—Methotrexate—psoriatic arthritis	0.0008	0.000835	CcSEcCtD
Nelarabine—Vomiting—Methotrexate—psoriatic arthritis	0.00077	0.000803	CcSEcCtD
Nelarabine—Headache—Methotrexate—psoriatic arthritis	0.000758	0.000791	CcSEcCtD
Nelarabine—Nausea—Methotrexate—psoriatic arthritis	0.000719	0.00075	CcSEcCtD
